Why the study?
Does recombinant human erythropoietin improve outcomes in patients with chronic heart failure and anemia?
Population
Patients with chronic heart failure and anemia, drawing parallels from chronic kidney disease patients.
Design
Review
Authors
Loading...
Should not yet change practice in anemic CHF; leaves open outcome benefits pending large confirmatory RCTs.
Does recombinant human erythropoietin improve outcomes in patients with chronic heart failure and anemia?
This review highlights the potential benefits of epoetin treatment for anemia in chronic heart failure, emphasizing the need for large RCTs to confirm morbidity and mortality improvements.
Besarab et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: